CLDN4 and ovarian carcinoma: Overall, these results suggest that targeting claudin-4’s functional effects through CMP and FSK reduces EOC cell survival during olaparib treatment, highlighting claudin-4’s potential to decrease olaparib resistance and promote ovarian cancer cell death.